Development of a monitoring and treatment regimen for NSG mice displaying phenotypic tarsal joint swelling and hock lesions



Cat Beatty¹, Sophie Garnham¹, Kate Brown¹, Sam Caunce¹, Jo Keeley², Tina O'Mahony², Jenny Parnell², Martyn Foster¹, Amy Warner¹

- 1. RxCelerate Ltd, The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, UK CB22 3FH
- 2. University Biomedical Services, Mira Building, University of Cambridge, Charles Babbage Rd, Cambridge, CB3 0FS

NSG (NOD.Cg-Prkdc^{scid}II2rg^{tm1WjI}/SzJ) mice are **severely immunocompromised** and require careful handling and strict biosafety protocols to maintain their health status.

Despite their genetic mutations, NSG mice typically do not display any gross physical or behavioural abnormalities (JAX, 2024). However, in recent years, we have observed a subset of NSGs (~30%) in our research labs developing a progressive tarsal lesion phenotype similar to that previously reported by MacLeod et al. (2017) in huNOG mice and Campagna et al. (2021) in NSG mice.

The phenotype initially presents as either unilateral or bilateral **rounding of the hock**, progressing to **swelling and reddening of the tarsal joint**, eventually advancing to **ulceration of the skin**. Toe **curl, grip strength and gait** are typically also impacted in the affected limb(s).

Using one of our internal R&D studies, we developed a scoring system and treatment plan to support affected animals through the acute phase, and subsequently collected samples to investigate the pathological changes occurring in the affected hocks.

Phenotype



R

Figure 1. Comparison of an affected left hock and healthy right hock in a female NSG mouse.

The left hock displays reddening and swelling of the heel *in vivo*. Histopathology indicated new cartilage and bone growth within the soft tissues of the hock. The right hock appears healthy *in vivo*, and histopathology was



unremarkable.

Monitoring & Treatment

Case Study:

- 5 female NSGs from Charles River UK arrived on 04/12/23 aged 6-7 weeks, were housed in an IVC under standard conditions, and acclimatised for 10 days.
- Tumour cells were injected into the mammary fat pad on 14/12/2023. Tumour volume and body weights were measured 3x weekly for 8 weeks. Animals did not receive any anti-cancer agents during the study.
- The first animal developed hock issues on 08/01/24 (4th week of study). Hock issues were observed in 4/5 animals by study end.
- A treatment regimen was developed in collaboration with the University of Cambridge NACWO/NVS team: a drop of Metacam (NSAID) orally twice daily for up to 10 days. Sudocrem applied to hock lesions once daily.
- Tumour growth was not impacted by Metacam treatment. All animals completed the study with minimal welfare implications or impact to our study data.



Pathology




Figure 3. Low power microscopic images of hock regions with skin removed and calcaneum and underlying subcutaneous tissue visible. (A) unremarkable, healthy tissue. (B) Acute inflammation and partial hyperplastic changes in subcutaneous tissue. (C) Acute inflammation, hyperplastic changes in the skin, and proliferative and metaplastic changes in the cartilage. Marked changes in the bone structure. (H&E Stain, 5x, Scale bar = 500 μ m). (D) Section of calcaneus showing denser areas of recent and immature bone formations (arrowheads), chondrocyte hypertrophy (star) and increased chondrocyte proliferation (crescent). Proliferative and hypertrophic chondrocytes are important steps in endochondral ossification – the replacement of cartilage with bone. (H&E stain, 10x, Scale bar = 100 μ m).

Day 1	Day 6	Week 3	Week 4	Week 5	
Daily scoring. Me	Daily scoring. Metacam treatment 2x daily		Scoring 3x weekly		

Figure 2. Example of hock phenotype development and treatment. Hock lesion, reddening, and swelling of both tarsal joints with slight toe curl. The mouse also presented with flat-footed gait and intermittent weight bearing during the acute treatment phase, however grip strength was normal. Metacam was administered twice daily for 7 days. The hock lesions scabbed and eventually healed, however the morphological changes (swelling, pinkness, altered gait) remained until study completion.

Table 1. Our proposed clinical scoring system to monitor progression of NSG hock issues.During the acute phase, animals are treated with Metacam for up to 10 days, and daily scores taken to assessfor positive treatment response. If animals present with hock lesions, sudocrem is also applied daily.

Clinical Score	0	1	2	3
Lesion	Normal	Skin thin and shiny	First skin layer broken	Wound through multiple tissue layers. Complications e.g. infection, necrosis
Swelling	No swelling	Rounding of hock	Widening of hock, darker shade of pink	Active inflammation, very red
Toe curling	Toes splayed	Toes together, minimal curling	Toes together, curled	Toes together, clenched
Grip	Normal	Strong grip	Weak grip	No grip
Movement	Normal	Slight change, not immediately obvious	Significant change e.g. waddling, rolling, or dragging foot	Loss of movement, hind limb paralysis

Husbandry & housing refinements:

 Bedding change from Aspen Eco Pure chips to Alpha Dri: less irritant and softer on the paws



• Animals handled on a soft surface only i.e. avoiding wire cage bars




Figure 4. Structural comparisons of skin between (A+B) a mouse presenting with inflammation and new bone and cartilage growth, and (C+D) a mouse demonstrating inflammation alongside keratosis and scabbing. The epidermis and dermis is markedly thicker when inflamed. (H&E stain, A+C 4x, B+D 20x, Scale bar = 100 μ m).

- NSGs appear to be quite an anxious strain, so providing additional enrichment is beneficial:
 - Seeds scattered in bedding to encourage foraging behaviour
 - Nesting material changed/provided more frequently (avid nest builders)
 - Chew blocks given to provide extra stimulus/discourage tail nipping
- Avoid the use of wheels or discs in the cage






Figure 5. Subcutaneous tissue of mouse hind paw displaying acute inflammation. Monocytes and neutrophils are identifiable throughout alongside the presence of defective macrophage. (H&E stain, 40x, Scale bar = 25 μ m).

Key Points

- There is acute inflammation and non-reversible, ectopic formation of cartilage and bone within the calcaneus tendon and heels.
- Our hypothesis is a **mass expansion of mesenchymal cells** is occurring in response to a trauma event (e.g. hyperextension or pressure on joint), leading to **endochondral ossification** (EO). In the EO bone formation pathway, mesenchymal tissue initially forms immature cartilage tissue which is then replaced with bone. The morphological changes observed *in vivo* e.g. swelling, lesions, change in gait and grip strength are a consequence of metaplastic cartilage and bone growth in the heel.
- Metacam provides rapid pain relief and prevents further inflammation occurring, thereby halting further lesion progression.
- The phenotype trigger is unknown. Increased stress levels appear to contribute to the development of these hock issues.

References

Campagna, M., Hernandez, A., Serrano, J., Schile, A., Doty, R., Ramsay, K., Maglaty, M., and Imai-Leonard, D. (2021). Evaluation of Tarsal Lesions in Immunocompromised Mouse Strains. J Am Assoc Lab Anim Sci. 60(5): 597-671.

MacLeod, A., Treuting, P., and Carlson, C. (2017). Proliferative Cartilaginous Lesions in the Calcaneal Tendons of huNOG Mice. *Toxicologic Pathology*. 45(7) 952-956. The Jackson Laboratory (2024). Available at: https://www.jax.org/strain/005557 (Accessed: 03 September 2024).